GlassScriptPhysician profile
James Lester Avery
NPI 1790080182
$1,302.21
in general payments reported to CMS, 2019-2025
23 companies · $425 in 2025
The $425 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $78.33 · 2022: $88.11 · 2023: $284 · 2024: $426 · 2025: $425.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,136.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,135.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $196.97 | 2024-2025 | Krystexxa, Otezla, Repatha |
| Abbvie INC. | $145.10 | 2022-2025 | |
| Abiomed | $137.14 | 2024 | Impella |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.91 | 2023-2025 | Jardiance, Ofev |
| Astrazeneca Pharmaceuticals LP | $79.44 | 2023-2025 | Farxiga, Breztri |
| Corcept Therapeutics | $70.93 | 2024-2025 | Korlym |
| Lilly USA, LLC | $68.51 | 2022-2025 | Mounjaro |
| Pfizer INC. | $57.55 | 2021-2024 | |
| Glaxosmithkline, LLC. | $56.15 | 2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Horizon Therapeutics Plc | $52.28 | 2023 | Krystexxa |
| Novo Nordisk INC | $44.76 | 2021-2023 | Rybelsus, Ozempic |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.72 | 2024 | Xifaxan |
| Exact Sciences Corporation | $38.69 | 2023-2025 | Cologuard Collection Kit |
| Boston Scientific Corporation | $36.74 | 2022-2023 | Exalt Model D |
| Xeris Pharmaceuticals, INC. | $33.21 | 2023-2025 | Gvoke Hypopen |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $27.64 | 2024 | Voquezna |
| Nevro Corp. | $23.07 | 2023 | Senza |
| Actelion Pharmaceuticals US, INC. | $21.27 | 2023 | Uptravi, Opsumit |
| Scilex Pharmaceuticals INC. | $17.18 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.30 | 2021 | |
| Vanda Pharmaceuticals INC. | $14.43 | 2025 | Fanapt, Hetlioz |
| Idorsia Pharmaceuticals US INC | $13.15 | 2023 | Quviviq |
| Biohaven Pharmaceutical Holding Company LTD. | $13.07 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Avery listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.